Merck (MRK) Divestments (2009 - 2021)

Merck's (MRK) quarterly Divestments came in at -$82.0 million in Q2 2021, down 57.69% quarter-over-quarter from -$52.0 million in Q1 2021.

Analysis

Merck (MRK) Divestments (2009 - 2021) Analysis & Trends

Merck (MRK) has reported Divestments for 7 consecutive years, with -$82.0 million the latest figure, recorded in Q2 2021.

On a quarterly basis, Divestments changed N/A year-over-year to -$82.0 million in Q2 2021; TTM through Mar 2022 was -$82.0 million, a 59.41% increase from a year earlier, with the FY2021 full-year figure at -$134.0 million, up 46.4% from the prior year.
Divestments was -$82.0 million for Q2 2021 at Merck, down from -$52.0 million in the prior quarter.
Over five years, Divestments peaked at -$52.0 million in Q1 2021 and troughed at -$82.0 million in Q2 2021.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Divestments (Qtr)
1	Johnson & Johnson	641.14 Bn	620.38 Bn	17.26 Bn	-
2	AbbVie	451.04 Bn	444.47 Bn	12.70 Bn	-
3	Merck	357.43 Bn	350.29 Bn	12.21 Bn	-
4	Novartis Ag	266.73 Bn	259.04 Bn	11.24 Bn	62.00 Mn
5	Pfizer	157.52 Bn	145.82 Bn	10.94 Bn	1.88 Bn
6	Sanofi	52.14 Bn	44.76 Bn	10.79 Bn	-
7	Revolution Medicines	42.88 Bn	42.88 Bn	-	-
8	Incyte	24.70 Bn	20.16 Bn	1.57 Bn	-
9	United Therapeutics	21.47 Bn	18.80 Bn	683.80 Mn	-
10	Neurocrine Biosciences	15.82 Bn	15.43 Bn	935.80 Mn	-

Historic Data

Download Data